SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up - Still a Buy?

Key Points

• SELLAS shares gapped up Monday — the stock opened at $4.74 vs. a $4.46 close and last traded at $4.9330, up about 9.9% on roughly 2.07 million shares.
• Analysts are mixed: MarketBeat shows a consensus "Hold" with an average price target of $10, while Maxim upgraded to a $10 Buy and Weiss Ratings reiterated a "Sell (D‑)".
• Company fundamentals include a ~$904M market cap and a negative PE (-19.6); SELLAS posted a slight quarterly EPS beat ($‑0.05 vs. $‑0.06) and is developing its WT1‑targeting vaccine galinpepimut‑S in clinical trials.

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report)'s stock price gapped up before the market opened on Monday . The stock had previously closed at $4.46, but opened at $4.74. SELLAS Life Sciences Group shares last traded at $4.9330, with a volume of 2,067,305 shares changing hands.

Analyst Ratings Changes

A number of analysts have recently commented on SLS shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a research note on Tuesday, April 21st. Maxim Group boosted their price objective on shares of SELLAS Life Sciences Group from $7.00 to $10.00 and gave the company a "buy" rating in a report on Thursday, March 12th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, SELLAS Life Sciences Group presently has a consensus rating of "Hold" and an average price target of $10.00.

SELLAS Life Sciences Group Stock Up 9.9%

The firm's fifty day moving average price is $4.81 and its two-hundred day moving average price is $3.43. The stock has a market capitalization of $904.20 million, a PE ratio of -19.60 and a beta of 2.22.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last released its quarterly earnings results on Thursday, March 19th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.01.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Axxcess Wealth Management LLC bought a new position in SELLAS Life Sciences Group in the third quarter worth approximately $26,000. Larson Financial Group LLC bought a new position in shares of SELLAS Life Sciences Group in the fourth quarter worth approximately $26,000. BNP Paribas Financial Markets boosted its position in shares of SELLAS Life Sciences Group by 89.2% in the third quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company's stock worth $32,000 after purchasing an additional 9,299 shares during the period. Concurrent Investment Advisors LLC bought a new position in shares of SELLAS Life Sciences Group in the fourth quarter worth approximately $38,000. Finally, Beacon Pointe Advisors LLC bought a new position in shares of SELLAS Life Sciences Group in the fourth quarter worth approximately $38,000. 17.38% of the stock is currently owned by institutional investors.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms' tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient's own immune system to recognize and attack WT1-positive cancer cells.

The company's lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.